Prognostic value of complete metabolic response on <sup>18</sup>F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer-Reference-Cited by-同舟云学术

Prognostic value of complete metabolic response on ¹⁸F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer

Published:2022 Issue:3 Volume:33 Page:
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Chung Young Shin¹^ORCID,Kim Yup¹^ORCID,Kim Hyun-Soo²^ORCID,Lee Jung-Yun¹^ORCID,Kang Won Jun³^ORCID,Kim Sunghoon¹^ORCID,Kim Sang Wun¹^ORCID

Affiliation:

1. Department of Obstetrics and Gynecology, Institution of Women’s Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.

2. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

3. Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, Korea.

Funder

Shin Poong Pharm. Co. Ltd.

Publisher

Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy

Subject

Obstetrics and Gynecology,Oncology,General Medicine

Link

https://ejgo.org/pdf/10.3802/jgo.2022.33.e28

Reference28 articles.

1. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

2. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

3. Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer

4. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer

5. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D;Journal for ImmunoTherapy of Cancer;2023-10

2. Predictive value of PET metabolic parameters for occult lymph node metastases in PET/CT defined node-negative patients with advanced epithelial ovarian cancer;Scientific Reports;2023-06-09

3. Predictive value of PET metabolic parameters for occult lymph node metastases in PET/CT defined node-negative patients with advanced epithelial ovarian cancer;2023-03-24